Loading...
Loading...
PXMD| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 4,364.5K |
| Operating I/L | -4,364.5K |
| Other Income/Expense | -684.7K |
| Interest Income | 0.0K |
| Pretax | -5,049.2K |
| Income Tax Expense | 1.3K |
| Net Income/Loss | -5,049.2K |
PaxMedica, Inc. is a clinical stage biopharmaceutical company specializing in the development of anti-purinergic drug therapies (APT) for challenging neurologic disorders. Its lead product candidate, PAX-101, is an intravenous formulation of suramin designed for conditions such as autism spectrum disorder, chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis. The company is also working on PAX-102, an intranasal formulation of suramin for neurologic indications. By focusing on the development and commercialization of these drug therapies, PaxMedica aims to generate revenue through the successful treatment of intractable neurologic symptoms.
